PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer

Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed ab immune-related ILC subset, and in mouse ILC models, synergy between immune checkpoint blockade and platinum was observed. The multicenter phase 2 GELATO trial in The Netherlands evaluated carboplatin as immune induction for 12 weeks, combined with atezolizumab from week 3 until disease progression, in patients with metastatic ILC. The clinical benefit rate was 26%. The authors conclude that PD-L1 blockade in combination with carboplatin had promising antitumor activity in patients with metastatic invasive lobular breast cancer.